Meningococcal disease

General Information

Meningococcal disease is caused by various serogroups of Neisseria meningitidis (N. meningitidis), of which groups A, B, C, W, Y account for about 95% of meningococcal disease. N. meningitidis is one of the most common causes of bacterial meningitis in the world and the only bacterium capable of generating large epidemics of meningitis.

Transmission

Meningococcus is transmitted by aerosol or direct contact with respiratory secretions of patients or healthy human carriers.

Symptoms

Meningitis and sepsis are the major clinical features of infection with N. meningitidis. Meningitis frequently presents with fever, headache and neck stiffness, and is often accompanied by other symptoms, such as altered mental status, nausea, vomiting and photophobia. Meningococcal sepsis is characterised by fever and a purpuric rash, often accompanied by septic shock, disseminated intravascular coagulation and multiple organ failure. Often a rapid progression of the disease, with an 8-15% case-fatality ratio. This may result in death within one or two days after onset of symptoms.

Epidemiology

2018

In 2018, 3,233 confirmed cases of invasive meningococcal disease (IMD), including 324 deaths, were reported in 30 EU/EEA Member States.​

Explosive epidemics with incidence rates of up to 1,000 cases per 100,000 inhabitants have been reported, particularly in sub-Saharan Africa.

MENINGOCOCCAL A, C, W, Y DISEASE

Vaccines Pipeline

2
Vaccines in
the pipeline

TECHNOLOGY PLATFORMS

Glycoconjugate vaccine (2)

DEVELOPMENT PHASES

Phase III (1)
Under review (1)

TRIAL POPULATION

Paediatric (2)​

MENINGOCOCCAL B DISEASE

Vaccines Pipeline

1
Vaccines in
the pipeline

TECHNOLOGY PLATFORMS

Protein subunit (1)

DEVELOPMENT PHASES

Phase II (1)

TRIAL POPULATION

Paediatric + Adults + Older Adults (1)

MENINGOCOCCAL A, B, C, W, Y DISEASE

Vaccines Pipeline

4
Vaccines in
the pipeline

TECHNOLOGY PLATFORMS

Protein subunit (1)
Multiple platforms (3)Phase II (2)
Phase III (2)

DEVELOPMENT PHASES

Phase II (2)
Phase III (2)

TRIAL POPULATION

Paediatric (2)
Paediatric + Adults (1)
N/A (1)

Source:
WHO. Meningococcal meningitis. [cited 2023 August]. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/meningococcal-meningitis.
ECDC. Meningococcal disease. [cited 2023 August]. Available from: https://www.ecdc.europa.eu/en/meningococcal-disease.
ECDC. Invasive meningococcal disease. Annual Epidemiological Report for 2018. 2018 [cited 2023 August]. Available from: https://www.ecdc. europa.eu/sites/default/files/documents/AER-Invasive-meningococcal-disease-2018.pdf.
Purmohamad A et al. Microb Pathog 2019;134:103571